Evidence map›Paper›PMID 36899955›Full record

ArticleCells2023

Increased Radiation Sensitivity in Patients with Phelan-McDermid Syndrome.

Sarah Jesse, Lukas Kuhlmann, Laura S Hildebrand, Henriette Magelssen, Martina Schmaus, Beate Timmermann, Stephanie Andres, Rainer Fietkau, Luitpold V Distel

Open access · goldFull text read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Radiation sensitivity in genetic tumour syndromes and how to test for them.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Sarah JesseDepartment of Neurology, Ulm University, 89081 Ulm, Germany.
Lukas KuhlmannDepartment of Radiation Biology, Erlangen University, 91054 Erlangen, Germany.ORCID 0000-0002-5795-0715
Laura S HildebrandDepartment of Radiation Biology, Erlangen University, 91054 Erlangen, Germany.ORCID 0000-0002-1522-9591
Henriette MagelssenDepartment of Oncology, Oslo University Hospital (The Norwegian Radium Hospital), 0424 Oslo, Norway.
Martina SchmausDepartment of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
Beate TimmermannClinic for Particle Therapy at WPE, University Hospital Essen, 45147 Essen, Germany.
Stephanie AndresMedicover München Ost MVZ, Humangenetik, 81667 Munich, Germany.
Rainer FietkauDepartment of Radiation Biology, Erlangen University, 91054 Erlangen, Germany.ORCID 0000-0003-4387-3285
Luitpold V DistelDepartment of Radiation Biology, Erlangen University, 91054 Erlangen, Germany.ORCID 0000-0002-8040-3226
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEMedicover · DEOslo University Hospital · NOUniversität Hamburg · DEUniversität Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phelan-McDermid syndrome is an inherited global developmental disorder commonly associated with autism spectrum disorder. Due to a significantly increased radiosensitivity, measured before the start of radiotherapy of a rhabdoid tumor in a child with Phelan-McDermid syndrome, the question arose whether other patients with this syndrome also have increased radiosensitivity. For this purpose, the radiation sensitivity of blood lymphocytes after irradiation with 2Gray was examined using the G0 three-color fluorescence in situ hybridization assay in a cohort of 20 patients with Phelan-McDermid syndrome from blood samples. The results were compared to healthy volunteers, breast cancer patients and rectal cancer patients. Independent of age and gender, all but two patients with Phelan-McDermid syndrome showed significantly increased radiosensitivity, with an average of 0.653 breaks per metaphase. These results correlated neither with the individual genetic findings nor with the individual clinical course, nor with the respective clinical severity of the disease. In our pilot study, we saw a significantly increased radiosensitivity in lymphocytes from patients with Phelan-McDermid syndrome, so pronounced that a dose reduction would be recommended if radiotherapy had to be performed. Ultimately, the question arises as to the interpretation of these data. There does not appear to be an increased risk of tumors in these patients, since tumors are rare overall. The question, therefore, arose as to whether our results could possibly be the basis for processes, such as aging/preaging, or, in this context, neurodegeneration. There are no data on this so far, but this issue should be pursued in further fundamentally based studies in order to better understand the pathophysiology of the syndrome.

Indexed as

Autism Spectrum DisorderNeoplasmsChildChromosome DeletionChromosome DisordersChromosomes, Human, Pair 22HumansIn Situ Hybridization, FluorescencePilot ProjectsSyndromeatypical teratoid rhabdoid tumorchromosomal aberrationsPhelan McDermid syndromeradiation sensitivitySHANK3 deficiency

Identifiers

PMID36899955
PMCPMC10000830
OpenAlexW4323365008

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read19
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.